CN2.SW Stock Analysis
CN
Avoid
Based on Eyestock quantitative analysis, CN2.SW`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The FIRDAPSE is also used for the treatment of adult patients in Canada with LEMS. The Company is also focused on initiating clinical trials of amifampridine in other ultra-rare neuromuscular conditions.